Royalty Pharma PLC
(FRA:RPD)
€
24.8
-0.21 (-0.84%)
Market Cap: 11.22 Bil
Enterprise Value: 16.75 Bil
PE Ratio: 10.45
PB Ratio: 1.73
GF Score: 78/100 Royalty Pharma PLC at Bank of America Global Healthcare Conference Transcript
May 10, 2023 / 09:20PM GMT
Release Date Price:
€30.7
(-2.66%)
Geoffrey Meacham
BofA Securities, Research Division - Research Analyst
Welcome to the afternoon sessions of the BofA Healthcare Conference. I'm Geoff Meacham. I'm the senior biopharma analyst. We're here today on stage, and we're thrilled to have Royalty Pharma, Terry Coyne, CFO; Marshall Urist, Head of R&I -- sorry, I'd say R&D. R&I.
Marshall Urist
Royalty Pharma plc - Executive VP and Head of Research & Investments
R&I, yes. Yes.
Geoffrey Meacham
BofA Securities, Research Division - Research Analyst
So Terry is just going to go through a couple of slides to set up the background of the company, and then we'll do some questions.
Terrance Coyne
Royalty Pharma plc - Executive VP & CFO
Great. Thanks, Geoff, and thanks for BofA for having us here. So these are our normal forward-looking statements.
Royalty Pharma is a fairly new public company. We went public in June of 2020, but we actually have been around for a long time as a private
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot